Byoung-Hoon Min1,2,3,4, Jun-Seop Shin1,2,3,4, Jong-Min Kim1,2,3,4, Seong-Jun Kang2, Hyun-Je Kim2, Il-Hee Yoon1,2,4, Su-Kyoung Park1, Ji-Won Choi1, Min-Suk Lee1, Chung-Gyu Park1,2,3,5,6. 1. Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea. 3. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 4. Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea. 5. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Pancreatic islet transplantation is currently proven as a promising treatment for type 1 diabetes patients with labile glycemic control and severe hypoglycemia unawareness. Upon islet transplantation, revascularization is essential for proper functioning of the transplanted islets. As IL-6 is important for endothelial cell survival and systemic inflammation related to xenograft, the effect of IL-6 receptor antagonist, tocilizumab, on revascularization of the transplanted islets was examined in pig to non-human primate islet xenotransplantation model. Also, the endothelial cell origin in a new vessel of the transplanted pig islets was determined. METHODS: Pig islets were isolated from designated pathogen-free (DPF) SNU miniature pigs and transplanted via portal vein into five streptozotocin-induced diabetic monkeys. One group (n = 2, basal group) was treated with anti-thymoglobulin (ATG), anti-CD40 antibody (2C10R4), sirolimus, and tacrolimus, and the other group was additionally given tocilizumab on top of basal immunosuppression (n = 3, Tocilizumab group). To confirm IL-6 blocking effect, C-reactive protein (CRP) levels and serum IL-6 concentration were measured. Scheduled biopsy of the margin of the posterior segment right lobe inferior of the liver was performed at 3 weeks after transplantation to assess the degree of revascularization of the transplanted islets. Immunohistochemical staining using anti-insulin, anti-CD31 antibodies, and lectin IB4 was conducted to find the origin of endothelial cells in the islet graft. RESULTS: CRP significantly increased at 1~2 days after transplantation in Basal group, but not in Tocilizumab group, and higher serum IL-6 concentration was measured in latter group, showing the biological potency of tocilizumab. In Basal group, well-developed endothelial cells were observed on the peri- and intraislet area, whereas the number of CD31+ cells in the intraislet space was significantly reduced in Tocilizumab group. Finally, new endothelial cells in the pig islet graft were positive for CD31, but not for lectin IB4, suggesting that they are originated from the recipient monkey. CONCLUSIONS: Our results demonstrated that tocilizumab can delay revascularization of the transplanted islet, although this effect had no significant correlation to the overall islet graft survival. In the pig to NHP islet xenotransplantation model, the endothelial cells from recipient monkey form new blood vessels in and around pig islets.
BACKGROUND:Pancreatic islet transplantation is currently proven as a promising treatment for type 1 diabetespatients with labile glycemic control and severe hypoglycemia unawareness. Upon islet transplantation, revascularization is essential for proper functioning of the transplanted islets. As IL-6 is important for endothelial cell survival and systemic inflammation related to xenograft, the effect of IL-6 receptor antagonist, tocilizumab, on revascularization of the transplanted islets was examined in pig to non-human primate islet xenotransplantation model. Also, the endothelial cell origin in a new vessel of the transplanted pig islets was determined. METHODS:Pig islets were isolated from designated pathogen-free (DPF) SNU miniature pigs and transplanted via portal vein into five streptozotocin-induced diabetic monkeys. One group (n = 2, basal group) was treated with anti-thymoglobulin (ATG), anti-CD40 antibody (2C10R4), sirolimus, and tacrolimus, and the other group was additionally given tocilizumab on top of basal immunosuppression (n = 3, Tocilizumab group). To confirm IL-6 blocking effect, C-reactive protein (CRP) levels and serum IL-6 concentration were measured. Scheduled biopsy of the margin of the posterior segment right lobe inferior of the liver was performed at 3 weeks after transplantation to assess the degree of revascularization of the transplanted islets. Immunohistochemical staining using anti-insulin, anti-CD31 antibodies, and lectin IB4 was conducted to find the origin of endothelial cells in the islet graft. RESULTS:CRP significantly increased at 1~2 days after transplantation in Basal group, but not in Tocilizumab group, and higher serum IL-6 concentration was measured in latter group, showing the biological potency of tocilizumab. In Basal group, well-developed endothelial cells were observed on the peri- and intraislet area, whereas the number of CD31+ cells in the intraislet space was significantly reduced in Tocilizumab group. Finally, new endothelial cells in the pig islet graft were positive for CD31, but not for lectin IB4, suggesting that they are originated from the recipient monkey. CONCLUSIONS: Our results demonstrated that tocilizumab can delay revascularization of the transplanted islet, although this effect had no significant correlation to the overall islet graft survival. In the pig to NHP islet xenotransplantation model, the endothelial cells from recipient monkey form new blood vessels in and around pig islets.
Authors: D C Brennan; H A Kopetskie; P H Sayre; R Alejandro; E Cagliero; A M J Shapiro; J S Goldstein; M R DesMarais; S Booher; P J Bianchine Journal: Am J Transplant Date: 2015-10-03 Impact factor: 8.086
Authors: Marcela Brissova; Alena Shostak; Masakazu Shiota; Peter O Wiebe; Greg Poffenberger; Jeannelle Kantz; Zhongyi Chen; Chad Carr; W Gray Jerome; Jin Chen; H Scott Baldwin; Wendell Nicholson; David M Bader; Thomas Jetton; Maureen Gannon; Alvin C Powers Journal: Diabetes Date: 2006-11 Impact factor: 9.461
Authors: J S Shin; J M Kim; J S Kim; B H Min; Y H Kim; H J Kim; J Y Jang; I H Yoon; H J Kang; J Kim; E S Hwang; D G Lim; W W Lee; J Ha; K C Jung; S H Park; S J Kim; C G Park Journal: Am J Transplant Date: 2015-06-10 Impact factor: 8.086
Authors: Juan L Contreras; Cheryl A Smyth; Christopher Eckstein; Guadalupe Bilbao; J Anthony Thompson; Carlton J Young; Devin E Eckhoff Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: Guoqiang Zhang; Hayato Iwase; Qi Li; Takayuki Yamamoto; Abhijit Jagdale; Mohamed B Ezzelarab; David Ayares; David K C Cooper; Hidetaka Hara; Gangcheng Wang Journal: Front Immunol Date: 2021-12-08 Impact factor: 7.561